MammaPrint is a genomic test designed to assess the risk of metastasis in patients with early-stage breast cancer. It analyses the expression of a specific set of 70 genes within the tumour tissue obtained from a biopsy or surgical sample. The primary purpose of the MammaPrint test is to help predict the likelihood of the cancer recurring within the next ten years.